Across TCGA pan-cancer cohorts, PRKN mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of PRKN’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where PRKN mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types PRKN is over-expressed in tumor, although a few such as CCRCC and LSCC show the opposite, repressed pattern.

CCRCC, LSCC, and HNSC are the cancer types where PRKN tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRKN mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	IV	−0.732	<.001	12	view →
LSCC	Male	III,IV	−0.808	<.001	9	view →
HNSC	All	All	−1.427	<.001	8	view →
LUAD	All	II,III,IV	−0.778	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: PRKN RNA expression & survival · all PRKN data types